Targeting TNFR2 as a novel therapeutic strategy for Alzheimer's diseaseOrti-Casan, N., Wu, Y., Naude, P. J. W., De Deyn, P. P., Zuhorn, I. S. & Eisel, U. L. M., 4-Feb-2019, In : Frontiers in Neuroscience. 13, 8 p., 49.
Research output: Contribution to journal › Article › Academic › peer-review
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia. Accumulating experimental evidence shows the important linkage between tumor necrosis factor-α (TNF) and AD, but the exact role of TNF in AD is still not completely understood. Although TNF-inhibitors are successfully used for treating several diseases, total inhibition of TNF can cause side effects, particularly in neurological diseases. This is attributed to the opposing roles of the two TNF receptors. TNF receptor 1 (TNFR1) predominantly mediates inflammatory and pro-apoptotic signaling pathways, whereas TNF receptor 2 (TNFR2) is neuroprotective and promotes tissue regeneration. Therefore, the specific activation of TNFR2 signaling, either by directly targeting TNFR2 via TNFR2 agonists or by blocking TNFR1 signaling with TNFR1-selective antagonists, seems a promising strategy for AD therapy. This mini-review discusses the involvement of TNFR2 and its signaling pathway in AD and outlines its potential application as therapeutic target. A better understanding of the function of TNFR2 may lead to the development of a treatment for AD.
|Number of pages||8|
|Journal||Frontiers in Neuroscience|
|Publication status||Published - 4-Feb-2019|
- tumor necrosis factor, Alzheimer's disease, neurodegeneration, neuroprotection, agonists, antagonists, TUMOR-NECROSIS-FACTOR, NF-KAPPA-B, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, FACTOR-ALPHA, MEMBRANE TNF, MEMORY DEFICITS, SOLUBLE TNF, RECEPTOR 2, ACTIVATION, OLIGODENDROCYTE